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Abstract
Background: Leigh Syndrome (LS) is a severe neurodegenerative disorder characterized by bilateral symmetrical
necrotic lesions in the basal ganglia and brainstem. Onset is in early infancy and prognosis is poor. Causative
mutations have been disclosed in mitochondrial DNA and nuclear genes affecting respiratory chain subunits and
assembly factors.
Case presentation: Here we report the clinical and molecular features of a 15-month-old female LS patient. Direct
sequencing of her muscle-derived mtDNA revealed the presence of two apparently homoplasmic variants: the
novel m.14792C > G and the already known m.14459G > A resulting in p.His16Asp change in cytochrome b (MT-
CYB) and p.Ala72Val substitution in ND6 subunit, respectively. The m.14459G > A was heteroplasmic in the
mother’s blood-derived DNA.
Conclusions: The m.14459G > A might lead to LS, complicated LS or Leber Optic Hereditary Neuropathy. A
comprehensive re-evaluation of previously described 14459G > A-mutated patients does not explain this large
clinical heterogeneity.
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1. Background
Leigh Syndrome (LS, OMIM 256000) is a subacute
necrotizing encephalomyelopathy characterized by bilat-
eral symmetrical necrotic lesions of gray matter nuclei
in the basal ganglia, diencephalon, cerebellum or brain-
stem. The onset is usually in early infancy and patients
manifest an heterogeneous set of symptoms, such as
regression or psychomotor delay, weakness, hypotonia,
truncal ataxia, intention tremor associated with lactic
acidosis in the blood, cerebrospinal fluid or urine. The
prognosis is poor and, in most cases, patients die before
age of 5 years. It is the most frequent cause of inherited
mitochondrial disorder in infancy (1:40,000) [1].
LS inheritance is complex since patients may present
mutations in mitochondrial DNA (mtDNA) or in
nuclear genes, which predominantly encode for proteins
involved in respiratory chain structure and assembly or
in coenzyme Q10 biogenesis [2]. Among maternally
inherited forms, most of the mutations lay within genes
encoding Complex I (ND1-6) and V (ATP6, ATP8)
mitochondrial subunits [3].
Here we report the clinical, biochemical and molecu-
lar features of a pediatric patient affected by Leigh Syn-
drome associated with the mitochondrial DNA mutation
m.14459G > A within MT-ND6 gene.
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2. Case Presentation
Case report
The proband is a 15-month-old female patient born
from healthy nonconsanguineous Italian parents after a
regular pregnancy and delivery. Feeding problems and
gastroesophageal reflux were noted from the first weeks
of life. At the age of 3 months, after the first vaccina-
tion, she started to present dystonic postures of the
trunk initially misdiagnosed as related to gastroesopha-
geal reflux. At the age of 5 months, after the second
vaccination, she started to present irritability, inconsol-
able crying, psychomotor regression and generalized sei-
zures. She was treated with endorectal diazepam, and
after that she had no others seizure episodes. At 7
months of age, after an intercurrent viral illness, she was
referred to our department in Pavia. The clinical picture
was characterized by psychomotor delay, dystonic-dyski-
netic tetraparesis, startle reaction to sudden acoustic sti-
muli, episodic central apneas. Plasma amino acids
revealed high level of alanine, valine, isoleucine and
lysine with abnormal ratio alanine:lysine (3.7, range of
normality = 1.5-2.5). Urinary organic acids revealed high
level of lactic, pyruvic, fumaric and 3-ketoglutaric acids.
High levels of lactic and pyruvic acids were also demon-
strated both in plasma and CSF. MRI showed bilateral
symmetric hyperintense lesions on T2-weighted images
in the basal ganglia, thalami and ventral mesencephalum
(Figure 1A). Brain CT scan didn’t show calcification.
Fundus oculi showed retinal depigmentation; assessment
of VEPs revealed evidence of a conduction delay and
ERG showed retinal involvement. Auditory brainstem
responses, ECG and echocardiogram were normal.
A treatment with riboflavine 50 mg/day, thiamine 150
mg/day 300 mg: 1/2 cp, carnitine 100 mg/kg/day was
started.
At 8 months of age she started to present external
ophthalmoplegia and absence of pupillary reaction.
Hereafter the clinical picture remained stable.
A muscle tissue biopsy was normal at the morphologi-
cal and histochemical studies, with the exception of a
mild increase in acid phosphatase staining at subsarco-
lemmal level in a few fibres.
Family history for neurological disorders was negative.
General clinical assessment of her mother was normal.
Figure 1 Neuroradiological and molecular features in our proband. A. Brain MRI showed bilateral symmetric hyperintense lesions on T2-
weighted images in the head of caudate, putamen (top left), thalami (top right) and ventral mesencephalum (bottom left); these lesions were
hypointense in T1-weighted images (bottom right). B. PCR-RFLP analysis of m.14459G > A mutation. The transition m.14459G > A creates a
restriction site for endonuclease MaeIII in mutated amplicons obtained using a modified primer set previously described (FOR14430*-RC14710)
producing two fragments of 251 and 29 base pairs (the latter is not visible on the agarose gel) while wild type molecules remain uncut. C. PCR-
RFLP analysis of m.14792C > G variant. The variant m.14792C > G is recognized by restriction endonuclease HinfI which cuts mutated PCR-
amplified fragments (encompassing 14400-14963 nucleotides) producing molecules of 392 and 171 base pairs. Control samples are from healthy
unrelated independent subjects.
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Results
Spectrophotometric determination of the activity of
mitochondrial Complex I in muscle showed a residual
activity of 36% compared to controls (CI/CS = 5.9 nM/
min/mg protein, control values = 16.5 ± 2.6 normalized
to citrate synthase, CS).
Large-scale mtDNA rearrangements and mtDNA
depletion was excluded by Southern Blot and quantita-
tive PCR assays on muscle-derived DNA.
Direct sequencing of muscle-derived mtDNA revealed
the presence of two apparently homoplasmic variants:
the novel m.14792C > G and the already known
m.14459G > A resulting in p.His16Asp change in cyto-
chrome b (MT-CYB) and p.Ala72Val substitution in
ND6 subunit, respectively. Their presence was con-
firmed by specific PCR-RFLP assays. The sequence also
showed that the patient belongs to the mitochondrial
haplogroup H2a2, consisting to European ethnic groups.
The mother’s mtDNA was homoplasmic for MT-CYB
variant and heteroplasmic for the MT-ND6 mutation
with a mutational load estimated less than 2% by PCR-
RFLP analysis (Figure 1B and Figure 1C).
3. Conclusions
The variant m.14459G > A has been so far reported in
six patients affected by Leber’s hereditary optic neuropa-
thy (LHON), in seven probands mainly showing dysto-
nia and in four LS/Leigh-like Syndrome (LLS) patients
[4-9]. Clinical, biochemical and genetical features of the
aforementioned probands are summarized in Table 1.
Phenotypic manifestations of this variant are expressed
in both sexes with approximately equal frequency. How-
ever, the reason for the striking difference in the clinical
outcome of the m.14459G > A mutation between
patients is unknown.
Patients so far described belong to different ethnic
groups and they likely present different mtDNA hap-
logroups although a precise definition of the haplotypes
is available in few subjects. The available haplotypes
include H, T (West Eurasia and Middle East) and D
(East Asia and Americas). This fact suggests that the
mutation arose independently several times in a period
of time relatively recent.
Although mitochondrial haplogroups could influence
the phenotypic expression of LHON and LS associated
variant [10-12], no evidence has been produced for
m.14459G > A and haplotype H2a2 disclosed in our
patient.
Clinical manifestations of m.14459G > A transition
seem to mainly affect central nervous system and skele-
tal muscle. CNS, brainstem and optic nerve are often
compromised but some patients may present more sys-
temic manifestations. Dystonia is the most occurring
feature described alone or associated to LS/LLS.
The transition m.14459G > A is considered a rare
causative mutation for LHON [13]. Our proband had
delayed VEP, together with signs of retinal involvement,
probably reflecting multiple sites of affection along the
optic pathways. The involvement of visual pathway in
14459G > A-mutated patients is generally a later event
in contrast to dystonia that develops in the early child-
hood. To date the co-existence of LLS and LHON has
been clearly described in a single proband [7].
Laboratory findings are inconsistent and the elevation
of lactate level in blood and/or CSF found in some LS
patients, as wells as in our proband, is not peculiar to
this molecular defect.
Neuroradiological examinations, when performed,
showed lesions in brainstem and basal ganglia in LS and
dystonia patients. A positive result at MRI investigation
could address the diagnosis of dystonia or LS although
exceptions to this correlation have been reported.
Muscle biopsy did not show striking signs of mito-
chondrial impairment: in our proband no ragged-red or
cytochrome c oxidase-negative fibers were observed.
Minor changes such as mild variations in fiber size and
accumulation of subsarcolemmal mitochondria have
been reported in a few patients [5,7,8]. As in the case of
other mutations affecting structure or assembly of Com-
plex I, histological analysis may not prove helpful in
uncovering mitochondrial pathology.
Spectrophotometric analysis of the activity of respira-
tory chain complexes has been reported in early onset
patients who underwent muscle biopsy. Residual activity
of Complex I ranges from 3 to 76% compared to con-
trol. Secondary defects have been also observed in Com-
plex III [5]. Fibroblasts culture established from two LS
patients confirmed a severe reduction of enzymatic
activity [6]. In our patient we observed a strong reduc-
tion of Complex I activity in skeletal muscle, compatible
with the marked hypotonia observed.
Analysis of transmitochondrial cybrids previously con-
firmed that m.14459G > A leads to the impairment of
Complex I activity [14].
No obvious correlation between mutant load and clin-
ical features is observed. High levels of heteroplasmy in
blood have been described in LHON, dystonia and LS
patients. In the first report [4], even an asymptomatic
subject had 99% of mutant mtDNA in lymphoblasts but
it was suggested that it could be due to an artifact of
transformation and cell culture [6]. Tissues derived from
LS patients generally present a virtually homoplasmic
state [6], as in the case of our proband. Conversely,
mutant DNA detected in blood from LHON patients
differs widely, with heteroplasmy ranging from 18 to
99%.
The pathological manifestation of the m.14459G > A
mutation is thought to be highly tissue-specific,
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Table 1 Clinical, biochemical and molecular features of m.14459G > A mutated patients
Reference Patient Sex Ethnic group Age Age
of
Onset
Phenotype Clinical features Neuroradiology Residual CI
activity
m.14459G
> A
Mutational
load (%)
Current
Study
A F Caucasian
Haplogroup
H2a2
18 m 2 m LS
+Dystonia
Psycomotor delay,
hypotonia,
dystonia.
MRI: lesions in the
basal ganglia and
mesencephalum.
36%
(muscle)
> 99
(muscle)
>99 (blood)
Shoffner
et al. [5]
B1-1
(proband)
F African-
American
19y 3 m LHON Loss of bilateral
vision, optic
atrophy
MRI: lesions in
caudate nucleus
and right putamen
3% (muscle) >99
Shoffner
et al. [5]
B1-2
(proband’s
mother)
F African-
American
42y 42y LHON Loss of bilateral
vision, optic
atrophy
NP NP 50
Shoffner
et al. [5]
B2 F Caucasian 13y 3y Dystonia Dysarthria,
dystonia,
quadriparesis
CT: bilateral
hipodensity in the
putamina. MRI:
bilateral lesions in
putamen and
caudate.
NP 50
Funalot
et al. [7]
C2 M Caucasian
Haplogroup T
†32y
suicide
18y LLS+LHON Bilateral visual
failure, hearing
loss, ataxia,
extrapiramidal
signs
MRI: hyperintensity
in dorsal midbrain;
bilateral lesions in
the third ventricle
walls.
NP 40
Gropman
et al. [9]
D1
(proband)
F Hispanic 4y 3y Dystonia Anarthria, dystonia,
spasticity,
encefalopathy,
neurofibromatosis
MRI: bilateral
hyperintensities of
the putamen. MRS:
elevated lactate.
76%
(muscle)
>99
Gropman
et al. [9]
D1-2
(proband’s
mother)
F Hispanic 35y 34y neurofibromatosis,
muscle weakness
MRI: bitemporal
signal abnormalities
NP >99
Gropman
et al. [9]
D1-3
(proband’s
brother)
M Hispanic 7y 2y Dystonia neurofibromatosis,
hemiparesis,
cognitive delay
MRI: right sided
putaminal infarcts,
thickened corpus
callosum
NP >99
Gropman
et al. [9]
D1-3
(maternal
cousin)
F Hispanic 5y 5y - Hemiparesis MRI: bilateral
putaminal infarcts
MRS: elevated
lactate
NP >99
Kirby et al.
[6]
E1-1 F ? †7y 9 m LS Motor delay,
hypotonia, seizure,
dystonia.
CT: bilateral low
density lesions of
the basal ganglia
25%
(fibroblasts)
97
(fibroblasts)
Kirby et al.
[6]
E1-2
(proband’s
brother)
M ? †10 m 3 m LS Hypotonia,
neurological and
developmental
regression, seizure.
Metabolic acidosis.
- 6% (muscle)
46% (liver)
97 (muscle,
liver)
Kirby et al.
[6]
E2 F ? †8 m 6 m LS Developmental
delay, athetosis,
hypotonia.
MRI: cerebral
atrophy,
involvement of
basal ganglia and
medial thalamic
nuclei.
15%
(fibroblasts)
16%
(muscle)
37% (liver)
97 (muscle,
liver)
Jun et al. [4] G1-1
(proband)
F Hispanic
(Native
American).
Haplogroup D
10y 2y Dystonia Dystonia,
corticospinal tract
dysfunction,
dysarthria.
CT: bilateral low
density lesions in
putamen
progressing to the
caudate
- 99 (blood)
Jun et al. [4] G1-2
(proband’s
brother)
M Hispanic
(Native
American).
Haplogroup D
13y 13y Dystonia Dystonia,
intellectual
impairmeint.
NP NP 99 (blood)
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depending also on the levels of heteroplasmy present
in each organ or tissue involved and this fact could
explain the different clinical phenotypes [5]. The exis-
tence of secondary mtDNA variants able to modify the
disease presentation of a primary mutation has been
suggested before [15,16]. In our proband, we observed
a novel homoplasmic variant m.14792C > G, which
was absent in 162 Italian healthy controls. The pro-
band’s mother was homoplasmic for this nucleotide
change (and heteroplasmic for the m.14459G > A
mutation). Since her general clinical assessment was
normal, the MT-CYB variant is unlikely to have a
pathogenic significance.
Unfortunately, no cytochrome b region sequence
data are available for the previously reported 14459G
> A-mutated subjects. Moreover, some of the reported
probands, who share the same maternal lineage, pre-
sent very heterogeneous symptoms [8,9]. These ele-
ments suggest that other factors, external to
mitochondrial DNA, are relevant to explain the clini-
cal heterogeneity of m.14459 mutation, making the
contribution to disease of the novel m.14792C > G
variant purely speculative. The assessment of respira-
tory chain activity in transmitochondrial cybrids
derived from the proband and her mother would be
helpful to settle this point but this analysis is unfortu-
nately not feasible, due to the unavailability of primary
cell cultures.
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Jun et al. [4] G1-3
(proband’s
mother)
F Hispanic
(Native
American).
Haplogroup D
32y 32y LHON Bilateral optic
atrophy.
NP NP 73 (blood)
Jun et al. [4] G1-4
(maternal
cousin)
M Hispanic
(Native
American).
Haplogroup D
? ? LHON - NP NP 99 (blood)
Jun et al. [4] G1-5
(maternal
relative)
M Hispanic
(Native
American).
Haplogroup D
? 5y Dystonia Dystonia CT: abnormal basal
ganglial lucencies
NP 99 (blood)
Tarnopolsky
et al. [8]
E1-1
(proband)
F Caucasian 45y 8y Dystonia Dystonia MRI: hiperintensities
signal in putamen
N 34 (blood)
Tarnopolsky
et al. [8]
E1-2
(proband’s
brother)
M Caucasian 49y 19y LHON Visual loss, hearing
loss
NP NP 18 (blood)
Tarnopolsky
et al. [8]
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brother)
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MRI: normal NP 26 (blood)
NP: not performed; CI: Complex I,% values refer to activity compared to controls.
Ronchi et al. BMC Neurology 2011, 11:85
http://www.biomedcentral.com/1471-2377/11/85
Page 5 of 6
MS and MM carried out the histological analysis. GPC, AB, PV conceived of
the study, partecipated in its design and coordination and helped to draft
the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 7 March 2011 Accepted: 12 July 2011 Published: 12 July 2011
References
1. Rahman S, Blok RB, Dahl HH, Leigh syndrome, et al: Clinical features and
biochemical and DNA abnormalities. Ann Neurol 1996, 39:343-51.
2. Tucker EJ, Compton AG, Thorburn DR: Recent advances in the genetics of
mitochondrial encephalopathies. Curr Neurol Neurosci Rep 2010, 10:277-85.
3. Wong LJ: Pathogenic mitochondrial DNA mutations in protein-coding
genes. Muscle Nerve 2007, 36:279-93.
4. Jun AS, Brown MD, Wallace DC: A mitochondrial DNA mutation at
nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene
associated with maternally inherited Leber hereditary optic neuropathy
and dystonia. Proc Natl Acad Sci USA 1994, 91:6206-10.
5. Shoffner JM, Brown MD, Stugard C, Jun AS, Pollock S, Haas RH, Kaufman A,
Koontz D, Kim Y, Graham JR, et al: Leber’s hereditary optic neuropathy
plus dystonia is caused by a mitochondrial DNA point mutation. Ann
Neurol 1995, 38:163-9.
6. Kirby DM, Kahler SG, Freckmann ML, Reddihough D, Thorburn DR: Leigh
disease caused by the mitochondrial DNA G14459A mutation in
unrelated families. Ann Neurol 2000, 48:102-4.
7. Funalot B, Reynier P, Vighetto A, Ranoux D, Bonnefont JP, Godinot C,
Malthièry Y, Mas JL: Leigh-like encephalopathy complicating Leber’s
hereditary optic neuropathy. Ann Neurol 2002, 52:374-7.
8. Tarnopolsky MA, Baker SK, Myint T, Maxner CE, Robitaille J, Robinson BH:
Clinical variability in maternally inherited leber hereditary optic neuropathy
with the G14459A mutation. Am J Med Genet A 2004, 124:372-6.
9. Gropman A, Chen TJ, Perng CL, Krasnewich D, Chernoff E, Tifft C, Wong LJ:
Variable clinical manifestation of homoplasmic G14459A mitochondrial
DNA mutation. Am J Med Genet A 2004, 124:377-82.
10. Torroni A, Petrozzi M, D’Urbano L, Sellitto D, Zeviani M, Carrara F,
Carducci C, Leuzzi V, Carelli V, Barboni P, De Negri A, Scozzari R: Haplotype
and phylogenetic analyses suggest that one European-specific mtDNA
background plays a role in the expression of Leber hereditary optic
neuropathy by increasing the penetrance of the primary mutations
11778 and 14484. Am J Hum Genet 1997, 60:1107-21.
11. Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A, Pyle A,
Elson J, Howell N, La Morgia C, Valentino ML, Huoponen K, Savontaus ML,
Nikoskelainen E, Sadun AA, Salomao SR, Belfort R Jr, Griffiths P, Man PY, de
Coo RF, Horvath R, Zeviani M, Smeets HJ, Torroni A, Chinnery PF: Clinical
expression of Leber hereditary optic neuropathy is affected by the
mitochondrial DNA-haplogroup background. Am J Hum Genet 2007,
81:228-33.
12. D’Aurelio M, Vives-Bauza C, Davidson MM, Manfredi G: Mitochondrial DNA
background modifies the bioenergetics of NARP/MILS ATP6 mutant
cells. Hum Mol Genet 2010, 19:374-86.
13. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF: Inherited
mitochondrial optic neuropathies. J Med Genet 2009, 46:145-58.
14. Jun AS, Trounce IA, Brown MD, Shoffner JM, Wallace DC: Use of
transmitochondrial cybrids to assign a complex I defect to the
mitochondrial DNA-encoded NADH dehydrogenase subunit 6 gene
mutation at nucleotide pair 14459 that causes Leber hereditary optic
neuropathy and dystonia. Mol Cell Biol 1996, 16:771-7.
15. Johns DR, Smith KH, Savino PJ, Miller NR: Leber’s hereditary optic
neuropathy. Clinical manifestations of the 15257 mutation.
Ophthalmology 1993, 100:981-6.
16. Lodi R, Montagna P, Cortelli P, Iotti S, Cevoli S, Carelli V, Barbiroli B:
’Secondary’ 4216/ND1 and 13708/ND5 Leber’s hereditary optic
neuropathy mitochondrial DNA mutations do not further impair in vivo
mitochondrial oxidative metabolism when associated with the 11778/
ND4 mitochondrial DNA mutation. Brain 2000, 123:1896-902.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/85/prepub
doi:10.1186/1471-2377-11-85
Cite this article as: Ronchi et al.: Clinical and molecular features of an
infant patient affected by Leigh Disease associated to m.14459G > A
mitochondrial DNA mutation: a case report. BMC Neurology 2011 11:85.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ronchi et al. BMC Neurology 2011, 11:85
http://www.biomedcentral.com/1471-2377/11/85
Page 6 of 6
